Recent Developments in Alzheimer’s Disease

Cras, Patrick

doi:10.1179/acb.2001.040

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2014

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 9 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite the use of modern diagnostic methods, neuroimaging examinations and genetic studies, there is still no single, practical, intravital method that would provide a definitive diagnosis of Alzheimer's disease (AD) [5].…”

Section: Introductionmentioning

confidence: 99%

The value of quantitative EEG in differential diagnosis of Alzheimer's disease and subcortical vascular dementia

Gaweł

Zalewska

Szmidt-Salkowska

et al. 2009

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The value of quantitative EEG in differential diagnosis of Alzheimer's disease and subcortical vascular dementia

Gaweł

Zalewska

Szmidt-Salkowska

et al. 2009

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Alzheimer’s disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications

Fivecoat

Wang

et al. 2010

Experimental Gerontology

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia in the elderly. Current treatments for AD are not as effective as needed, nor is there any definitive antemortem diagnostic. Understanding the biological processes that occur during AD onset and/or progression will improve disease diagnosis and treatment. Recent applications of microarray technologies for analysis of messenger (m) RNA expression profiles have elucidated distinct changes in the brain as a function of AD dementia initiation and progression. However, mRNA analysis underestimates posttranscriptional modifications and therefore provides only a partial view of the molecular changes in the AD brain. Combining mRNA studies with protein expression analysis may provide a more global picture of the biological processes associated with AD dementia. Information gathered could lead to the development of select biological indices (biomarkers) for guiding AD diagnosis and therapy. We will provide a brief background on AD, followed by a review on the applications of microarray, proteomics, as well as microRNA expression profile analysis to develop novel diagnostic strategies that may be useful for the diagnosis AD and for monitoring disease progression. The availability of biomarkers that promote early disease diagnosis, particularly among asymptomatic patients, will lead to the application of personalized medicine in AD.

show abstract